Reminder: Invitation to Roche's Virtual Early Drug Development gRED Event 2020
We are pleased to invite investors and analysts to participate in a live video webcast and conference call on Tuesday, February 18, 2020, highlighting Roche's early drug development with a focus on Genentech Research and Early Development (gRED).
We would like to invite all interested parties to dial in as outlined below:
Tuesday, February 18, 2020
15:30 - 17:00 CET/ 14:30 - 16:00 GMT
9:30 am - 11:00 am EST / 6:30 am - 8:00 am PST
Video webcast and conference call will start with presentations by senior researchers followed by a Q&A session (live access to the speakers).
Agenda:
Welcome
Karl Mahler, Head of Investor Relations and Roche Group Planning
Overview and Introduction to Genentech (gRED)
Michael Varney, Head of Genentech Research and Early Development
Non-Oncology Pipeline Overview
Andy Chan, Senior Vice President, Research Biology for gRED
Oncology Pipeline Overview
Stuart Lutzker, Vice President, Oncology Research and ad interim Head of Early Clinical Development for gRED
Cancer Immunotherapy
Ira Mellman, Vice President, Cancer Immunology and Immunology for gRED
Access to Video Webcast
Please access by clicking on >ir.roche.com
Access to Conference Call (pre-registration required)
You will receive phone numbers, passcode and your personal PIN to direct access the conference call by pre-registering here.
Should you have any issues with the registration, please dial the following numbers on the day of the conference call 10-15 minutes prior to conference start:
+41 (0) 58 310 50 00 (Europe & RoW)
+44 (0) 207 107 06 13 (UK)
+1 (1) 631 570 5613 (USA)
A replay of the webcast will be available via >ir.roche.com
Attachments
- Original document
- Permalink
Disclaimer
Roche Holding AG published this content on 11 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 February 2020 13:07:03 UTC